Abstract 90P
Background
Immune surveillance is closely related to MHC and its associated molecules. The MHC class I chain related B molecule (MICB) is one of the ligands of NKG2D receptor. NKG2D receptor exists in NK cells and CD8+ T cells, which mediate anti-tumor response and immune surveillance. MICB is expressed by intestinal epithelium and epithelial tumors as well. Cancer cells express MICB as the consequence of cellular stress. But tumor cells might develop evasive pathways to avoid NK cell attack. Shedding is a way for cancer cells to remove or avoid the surface expression of MICB. Previous studies haven’t clearly figured out the prognostic value of MICB in colorectal cancer (CRC). Here, we figured out the relationship between MICB and prognosis in a CRC cohort of Zhongshan Hospital. The prognostic benefit was also validated in GSE39582 from Gene Expression Omnibus repository.
Methods
863 consecutive CRC patients from 2008 to 2012 without prior treatment were enrolled. 556 CRC patients between 1987 to 2007 were collected from GSE39582. MICB was detected by immunochemistry. MICB score equaled MICB intensity multiplied by the percentage of positive cells among all tumor cells. The cut-off value of MICB score was calculated by X-tile. The association between clinicopathological features and MICB were accessed by chi-square test. Kaplan-Meier analysis and log-rank test were performed to evaluate the relationship between MICB and overall survival. Univariate and multivariate cox regression analyses were performed to identify the independent prognostic factors.
Results
High MICB was significantly associated with non-mucinous histological type (p < 0.001) and ≤4.0cm tumor size (p = 0.001). Kaplan-Meier analyses and log-rank test showed high MICB group had a better overall survival (p = 0.002). In cox regression analyses of Zhongshan cohort, MICB was confirmed as an independent prognostic factor of OS (p = 0.008, HR = 0.741, 95% CI = 0.594-0.924).
Conclusions
MICB was identified as a new independent prognostic factor in stage one to stage four CRC patients. CRC with high MICB expression conferred survival benefit.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongshan Hospital, Fudan University, Shanghai, China.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract